• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About
  • Consumer Info
  • Guideline Notes
  • Medicine and Media
  • Pharmacogenomics
  • Visit My Etsy Store

Digital PharmD

Informatics in Pharmacy

AHA Lipid Guidelines

August 12, 2018 By Dr. G, PharmD

Print Friendly, PDF & Email
Risk GroupIntensity of TherapyDesired LDL-C Lowering
Moderate ASCVDModerate Intensity Statin30-50%
Established ASCVD or DM + 10 year risk > 7.5%High-intensity statin>50%

High-Intensity Statins

  • atorvastatin – 40-80 mg
  • rosuvastatin – 20-40 mg

Moderate Intensity Statins

  • atorvastatin – 10-20 mg
  • rosuvastatin – 5-10 mg
  • simvastatin – 20-40 mg
  • pravastatin – 40-80 mg
  • lovastatin – 40 mg
  • fluvastatin – 80 mg
  • pitavastatin – 2-4 mg

Goals:

  • Total cholesterol: <200 mg/dl
  • Triglycerides:  <150 mg/dl
  • HDL men >=40, women >=50

When to start therapy:

  • LDL over 190 mg/dl
  • LDL 70-189 and age 40-75 if:
    • Diabetes
    • 10-year ASCVD risk = 7.5% or more
      • recalculate score for ages 40-75 every 4-6 years
  • Only target triglycerides if over 500.
    • Increases in TGs caused by obesity, alcohol use, beta-blockers, olanzapine, and diabetes
  • Increased LDL is associated with gout

Filed Under: Cardiology Tagged With: lipids

Primary Sidebar

Newsletter

More to See

What You Need to Know About the 2022 Avian Influenza Outbreak

March 20, 2022 By Dr. G, PharmD

Endocarditis Guideline Review

February 24, 2022 By Dr. G, PharmD

Sinus Troubles: When Should I See My Doctor

January 5, 2022 By Dr. G, PharmD

Tags

acid base acidosis acute coronary syndrome alkalosis analgesics anaphylaxis aortic dissection arrhythmia Beta-Blockers biostatistics blood pressure cardiac markers CHA2DS2-VasC cocaine COVID-19 diabetes diabetes inspidius Guidelines heart failure Heparin hypersensitivity hypertension hypovolemic shock intubation ionotropes journal club lipids LMWH medication safety morphine conversions myocardial infarction needs work NOAC NSTEMI obstructive shock pharmacoeconomics pheochromocytoma pressors reference materials right mi sedation septic shock shock STEMI Updated 2020

Footer

Medical Disclaimer

The medical information on this website is provided “as is” without any representations or warranties, express or implied. GoPharmD makes no representations or warranties in relation to the medical information on this website.

GoPharmD does not warrant that:

  • the medical information on this website will be constantly available, or available at all; or
  • the medical information on this website is complete, true, accurate, up-to-date, or non-misleading.
  • You must not rely on the information on this website as an alternative to medical advice from your doctor or other professional healthcare provider.
  • If you have any specific questions about any medical matter you should consult your doctor or other professional healthcare provider.

Recent

  • Smoking
  • What You Need to Know About the 2022 Avian Influenza Outbreak
  • Endocarditis Guideline Review
  • Sinus Troubles: When Should I See My Doctor
  • Common Pharmacogenomic SNPs and Interactions

Search

Tags

acid base acidosis acute coronary syndrome alkalosis analgesics anaphylaxis aortic dissection arrhythmia Beta-Blockers biostatistics blood pressure cardiac markers CHA2DS2-VasC cocaine COVID-19 diabetes diabetes inspidius Guidelines heart failure Heparin hypersensitivity hypertension hypovolemic shock intubation ionotropes journal club lipids LMWH medication safety morphine conversions myocardial infarction needs work NOAC NSTEMI obstructive shock pharmacoeconomics pheochromocytoma pressors reference materials right mi sedation septic shock shock STEMI Updated 2020